Climb Bio, Inc(CLYM) - 2025 Q4 - Annual Results

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Exhibit 99.1 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, ...